The Department of Health and Human Services, through the NIH, has issued a Notice of Funding Opportunity (NOFO) aimed at expanding the existing Somatic Cell Genome Editing (SCGE) program. This initiative seeks applications for competitive revisions under funding opportunity RFA-RM-24-008, focusing on clinical trials for therapeutics developed under prior awards (RFA-RM-22-015) that did not initially permit clinical trials. The current funding will support first-in-human genome editing clinical trials, including necessary preparatory activities like patient recruitment and regulatory approvals. Key activities encompass developing clinical trial designs, manufacturing materials, and preparing IND applications, with a focus on health disparities and community engagement. The program emphasizes collaboration among awardees, NIH staff, and community partners to optimize and demonstrate efficacious genome editing therapeutics. With an anticipated budget contingent on existing awards and an emphasis on rigorous scientific merit, the NOFO establishes clear eligibility criteria, review processes, and milestones for assessing progress. Applications are due by specific dates and must adhere to detailed submission guidelines and regulations. This effort aims to drive forward the therapeutic application of genome editing, addressing critical barriers to treatment for genetic diseases.